Ribon Therapeutics

company

About

Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.

  • 1 - 10

Details

Last Funding Type
Series C
Last Funding Money Raised
$65M
Industries
Biotechnology,Health Care,Medical Device,Therapeutics
Founded date
Jan 1, 2015
Number Of Employee
1 - 10
Operating Status
Active

Ribon Therapeutics is a biotechnology company pioneering the discovery of new cancer medicines that target monoPARP proteins, critical regulators of cancer survival mechanisms.

The diverse and central functions that PARPs, or poly(ADP-ribose) polymerases, play in cancer cell survival pathways are just emerging, and many of the seminal discoveries in the field have been made by Ribon’s scientific founders. By combining insights from our founders and an experienced management team, Ribon is building a proprietary drug discovery platform to investigate the molecular action and biological function of a subset of the PARP protein family, called monoPARPs. Based on its platform, Ribon is creating a pipeline of innovative medicines that selectively target monoPARPs to treat cancer and may have the potential to impact other diseases. The company is backed by prominent life science investors, including The Column Group, U.S. Venture Partners, Deerfield Management and Osage University Partners.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$65M
Ribon Therapeutics has raised a total of $65M in funding over 2 rounds. Their latest funding was raised on Jun 14, 2021 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 14, 2021 Series C $65M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Ribon Therapeutics is funded by 1 investors. Avego Bioscience Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Avego Bioscience Capital Series C